Re­ju­ve­nate Bio shrinks staff, pipeline fo­cus as George Church spin­out eyes 2024 gene ther­a­py IND

Like many oth­er biotechs in this mar­ket en­vi­ron­ment, small gene ther­a­py mak­er Re­ju­ve­nate Bio has strug­gled to re­ju­ve­nate its bank ac­count.

The San Diego start­up, born out of George Church’s lab and the Wyss In­sti­tute, has laid off a siz­able por­tion of its work­force and slimmed down its pipeline ac­tiv­i­ty af­ter strug­gling with fund­ing, ac­cord­ing to LinkedIn posts. Work­ers at the biotech, fo­cused on ag­ing-re­lat­ed dis­eases for both hu­mans and dogs, post­ed in re­cent days to say the lay­offs af­fect­ed at least half of the com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.